What type of drug is xylazine

Meyer, M. Meyer, B. Mischo, O. Schofer, and H. Silva-Torres et al. Reyes, J. View at: Google Scholar A. Samanta, C. Roffe, and K. Tesfamariam and A. Chamorro-Jorganes, E. Araldi, and Y. Schwartz, R. Miller-Niehs, F.

Robertson et al. View at: Google Scholar R. Roberts, R. Smith, S. Safe, C. Szabo, R. Tjalkens, and F. Kielland, T. Blom, K. Nandakumar, R. Holmdahl, R. Blomhoff, and H. Girouard, G. Wang, E. Gallo et al. Fernandes, D. Costa, S. Toste, J. Lima, and S. Tedgui and Z. Silva-Torres, C. Lyvia Alvarez, J.

Ortiz, and B. View at: Google Scholar P. Hsiao, M. Chang, W. Cheng et al. Bocock, C. Edgell, H. Marr, and A. Schmitt, E. Heiss, Y. Aristei, T. Severin, and V. Manohar, A. Pepe, C. Zayas, S. Malhotra, and D. Jos, F. Moreno, and A. Park, Y. Li, and Y. Li, B. Zhang, K. Huang et al.

View at: Google Scholar T. Misko, R. Schilling, D. Salvemini, W. Moore, and M. Kleinhenz, X. Fan, J. Rubin, and C. Cox, C. Rosado-Berrios et al. Cincinelli, L. Musso, S. Dallavalle et al. Park, S. Kang, K. Yoo et al. Zou, D. Zhao, and Z. Afzal, S. Kumar, M. Haider et al. Ferrara and E. Sen, B. Das, A. Ganguly et al. Ganguly, T. Mukherjee, S. Bandyopadhyay, and H. Singhal, P. Sharma, A.

Kapasi, K. Reddy, N. Franki, and N. Singhal, M. Bhaskaran, J. Patel et al. Tan, Z. Li, S. Ma et al. Yin, M. Woodruff, Y. Zhang et al. Mongia, M. Bhaskaran, K. Manjappa, N. Baqi, and P. Pautz, R. Franzen, S. Dorsch et al. Kvietys and D. Kerns, L. Schwartz, K. Blanchard et al. Verma, M. Buchanan, and T. Verneuil, C. Leboeuf, J. Vidal et al. Neumann, H. Alsaffar, N.

Gertzberg, and A. Cunha-Oliveira, L. Silva, A. Moreno, C. Oliveira, and M. View at: Google Scholar J. He, Y. Xiao, and L. View at: Google Scholar G. Sudeshna and K. Tyagi et al. Cancer Res. View at: Google Scholar I. Salles-Passador, A. Fotedar, and R. Ling, A. Priebe, and R. View at: Google Scholar M.

Murata, M. Mizutani, S. Oikawa, Y. Hiraku, and S. Liao and C. Roos and B. Pietenpol and Z. In humans, it could cause central nervous system depression, respiratory depression, bradycardia, hypotension, and even death. Most of the non-fatal cases required medical intervention. Over recent years xylazine has emerged as an adulterant in recreational drugs, such as heroin or speedball a cocaine and heroin mixture.

Its chronic use is reported to be associated with physical deterioration and skin ulceration. Literature shows some similar pharmacologic effects between xylazine and heroin in humans. These similar pharmacologic effects may create synergistic toxic effects in humans.